Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 1.00 |
| ▸ | FAAH | O00519 | 6/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916928 | 0.90 | MGLL (0.81) | MGLLFAAHKMT2ANPSR1KDM4E | |
| SCHEMBL916475 | 0.90 | MGLL (0.81) | MGLLFAAHNPSR1KDM4ECACNA2D1 | |
| SCHEMBL13246546 | 0.90 | MGLL (0.81) | MGLLFAAHKMT2ANPSR1KDM4E | |
| SCHEMBL13246559 | 0.85 | MGLL (0.74) | MGLLFAAH | |
| SCHEMBL916881 | 0.85 | MGLL (0.73) | MGLLFAAH | |
| SCHEMBL917124 | 0.82 | MGLL (0.69) | MGLLFAAHKMT2ANPSR1KDM4E | |
| SCHEMBL13246508 | 0.80 | MGLL (0.67) | MGLLFAAHKMT2AALDH1A1MEN1 | |
| SCHEMBL31023668 | 0.80 | MGLL (0.65) | MGLLFAAHKMT2ANPSR1KDM4E | |
| SCHEMBL3231181 | 0.79 | MGLL (0.65) | MGLLFAAH | |
| SCHEMBL13246486 | 0.79 | MGLL (0.65) | MGLLFAAHKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | claimed |
| EP-2146991-B1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | claimed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | US | disclosed |
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| EP-2146991-B1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2146991-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008145842-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885KMT2A 951/4885 |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885KMT2A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.